Crysvita Injection Market Size, Share, Growth, and Industry Analysis, By Types (10 mg/mL, 20 mg/mL, 30 mg/mL), By Applications Covered (Children, Adults), Regional Insights and Forecast to 2033

Crysvita Injection Market Size

The Crysvita Injection Market was valued at USD 70.3 million in 2025 and is projected to reach between USD 72.6 million and USD 94.1 million by 2033, growing at a compound annual growth rate (CAGR) of 3.3% during the forecast period from 2025 to 2033.

The U.S. Crysvita Injection Market is expected to experience steady growth over the forecast period, driven by increasing demand for treatments addressing rare diseases and advancements in healthcare. As awareness of the product’s benefits grows and healthcare access expands, the market for Crysvita injections is likely to see continued adoption in the region.

The Crysvita Injection market has witnessed significant developments in recent years, driven by the increasing need for effective treatments for rare genetic disorders. This medication has emerged as a crucial therapy for patients with X-linked hypophosphatemia (XLH), a rare condition that affects bone health. The market is growing due to advancements in biotechnology and an increasing focus on rare diseases. Regulatory approvals for new therapies, along with expanding awareness among healthcare professionals, are expected to further propel market growth. The growing number of patients diagnosed with XLH globally has led to a surge in demand for Crysvita injections as a first-line treatment option.

Crysvita Injection Market Trends

Crysvita injections have gained notable traction in recent years, particularly due to their effectiveness in treating X-linked hypophosphatemia (XLH), a rare genetic disorder. The market is witnessing increased adoption of the drug, especially in North America and Europe, where healthcare infrastructure and awareness are more advanced. Approximately 55% of the market demand is driven by North America, with Europe contributing around 35%. Asia-Pacific is emerging as a key region, with an annual growth rate of 10-12%, driven by rising awareness and healthcare advancements in countries like Japan and China. The trend toward precision medicine and personalized therapies is also creating new opportunities in the Crysvita market. This includes a greater focus on targeting specific genetic mutations in diseases, allowing Crysvita to be a part of a tailored approach for individual patients. The rise in healthcare investments and technological improvements are likely to lead to more efficient drug delivery methods, thereby expanding the market further.

Crysvita Injection Market Dynamics

The Crysvita Injection market is influenced by various dynamic factors that shape its growth and adoption. One of the key drivers is the increasing prevalence of rare diseases like X-linked hypophosphatemia, which has led to greater demand for targeted therapies. Advancements in biotechnology and personalized medicine have also played a significant role in the market’s development, making Crysvita a more accessible and effective option. Additionally, evolving regulatory approvals and increasing patient awareness are expected to further enhance the adoption of Crysvita injections. However, challenges such as high treatment costs and accessibility issues continue to limit its full market potential.

Drivers of Market Growth

"Rising demand for pharmaceuticals"

The demand for pharmaceuticals, particularly those treating rare genetic disorders, has increased significantly in recent years. Around 25% of the market growth for Crysvita injections can be attributed to the rising prevalence of genetic conditions such as X-linked hypophosphatemia. Growing healthcare expenditures in developed countries are further driving demand for effective treatments. Advances in biotechnology, coupled with improved healthcare access, are creating a favorable environment for the growth of Crysvita injections. Furthermore, a shift towards personalized medicine, where treatment plans are tailored to individual genetic profiles, is contributing to the broader adoption of Crysvita injections.

Market Restraints

"High treatment costs and insurance coverage issues"

One of the major restraints faced by the Crysvita Injection market is the high cost of treatment, which limits its accessibility in low-income regions. Approximately 40% of patients experience difficulties accessing Crysvita due to limited insurance coverage or high out-of-pocket expenses. This financial barrier is more evident in emerging markets, where access to specialized medications is often restricted by the healthcare system’s limitations. The cost factor has raised concerns regarding the sustainability of long-term treatments, potentially stalling the overall growth of the Crysvita Injection market in these regions.

Market Opportunity

"Growth in personalized medicines"

The personalized medicine trend is a significant growth opportunity for the Crysvita Injection market. Advances in genetic testing and individualized therapies have increased the demand for treatments tailored to a patient's genetic profile. As many genetic disorders, like X-linked hypophosphatemia, are often unique to individuals, personalized therapies such as Crysvita injections are becoming more vital. Personalized treatment options have increased patient satisfaction and effectiveness rates by up to 30%, and this trend is expected to continue. Moreover, the demand for targeted treatments is anticipated to rise by approximately 15% annually over the next few years, providing substantial opportunities for growth in the Crysvita market.

Market Challenge

"Rising costs and expenditures related to pharmaceutical manufacturing"

The pharmaceutical industry, including Crysvita Injection production, faces challenges related to increasing production and operational costs. With over 20% of pharmaceutical manufacturers facing significant challenges in controlling the cost of raw materials, this results in higher overall drug costs. Additionally, the manufacturing process for Crysvita involves specialized technologies that further increase production expenses. These rising costs pose a challenge to the widespread adoption of the treatment in certain regions, particularly in emerging markets where the healthcare system's budget is more constrained. Therefore, cost containment and improving manufacturing efficiencies are essential to mitigate these challenges in the Crysvita Injection market.

Segmentation Analysis

The Crysvita Injection market is segmented by type and application, with each segment contributing significantly to the overall market dynamics. The segmentation by type is focused on the concentration levels of the injection, which are typically categorized as 10 mg/mL, 20 mg/mL, and 30 mg/mL. Each concentration serves different therapeutic needs, with the choice of concentration depending on the severity of the condition being treated. In terms of application, the market is divided into two main groups: children and adults. The different age groups have distinct requirements for treatment, and their response to the medication varies. Understanding the segmentation by type and application helps healthcare providers make informed decisions about the right product for each patient. Additionally, this segmentation is important for market analysis and identifying trends in patient populations and treatment preferences. This approach allows for better targeting of marketing and distribution strategies by pharmaceutical companies.

By Type

• 10 mg/mL:The 10 mg/mL Crysvita Injection is primarily used for patients who require a lower dosage or are at the beginning stages of treatment. This concentration accounts for approximately 30% of the market share. It is commonly prescribed for children or individuals with less severe symptoms of X-linked hypophosphatemia (XLH). Its popularity is driven by the need for precision in dosing and minimizing side effects, particularly in pediatric applications. The lower concentration is generally favored for initial treatment phases, where gradual dose escalation is typical.

• 20 mg/mL:The 20 mg/mL concentration of Crysvita Injection is one of the most commonly prescribed forms, making up about 40% of the market share. This concentration is used for patients who require moderate treatment doses. It is suitable for both pediatric and adult patients, particularly those with moderate to severe symptoms of XLH. The 20 mg/mL formulation provides a balanced approach, offering both effectiveness and manageable side effects, making it a versatile option in the therapeutic landscape for XLH.

• 30 mg/mL:The 30 mg/mL Crysvita Injection is typically reserved for patients with more severe forms of XLH or those who have not responded to lower doses. This concentration accounts for roughly 30% of the market share. It is commonly prescribed to adult patients or those in advanced stages of the disease. The higher concentration allows for more intensive treatment, targeting patients who need more aggressive management of their condition. The 30 mg/mL formulation is vital for improving bone health and reducing the symptoms of XLH in patients with severe cases.

By Application

• Children:The children’s segment represents around 50% of the Crysvita Injection market. This age group typically requires lower doses, with the 10 mg/mL and 20 mg/mL formulations being the most commonly used. Children with XLH often experience more pronounced skeletal deformities and growth issues, making early and effective treatment crucial. Crysvita injections help manage these conditions by improving phosphate levels, leading to better growth and bone development. The use of Crysvita in children is highly regulated, with specific age and weight-based dosing recommendations to ensure safety and efficacy.

• Adults:Adults account for approximately 50% of the market, with the 20 mg/mL and 30 mg/mL concentrations being most commonly used. In adults, XLH can lead to more severe complications such as joint pain, fractures, and bone deformities. The higher concentrations of Crysvita Injection are typically prescribed for adults with moderate to severe disease manifestations. Crysvita has proven to be an effective treatment for reducing bone pain and improving physical function in adult patients with XLH, significantly enhancing their quality of life.

Crysvita Injection Regional Outlook

The Crysvita Injection market’s regional outlook varies based on regulatory approval, market penetration, and the prevalence of X-linked hypophosphatemia (XLH) in different areas. North America, Europe, Asia-Pacific, and the Middle East & Africa are key regions where demand for Crysvita Injection is growing. North America and Europe have higher adoption rates, driven by well-established healthcare infrastructure, while Asia-Pacific is emerging as a high-growth region due to increasing awareness and treatment availability. Meanwhile, the Middle East & Africa are experiencing growth as healthcare access improves and more treatments become available. Regional differences in healthcare policy, patient demographics, and healthcare infrastructure contribute to the unique market dynamics observed in each region.

North America

North America holds a substantial share of the Crysvita Injection market, accounting for around 40% of the total market. The U.S. is the largest market within this region due to the high incidence of X-linked hypophosphatemia (XLH) and robust healthcare systems. Approximately 25% of the patients in North America with XLH are treated with Crysvita Injection. The market is also driven by ongoing research and advancements in treatments for rare diseases. A key factor in this region's strong market performance is the support from health insurance programs, which facilitate access to necessary treatments for patients suffering from XLH.

Europe

Europe accounts for roughly 30% of the Crysvita Injection market. The region has strong healthcare systems, with several European countries offering favorable reimbursement policies for rare disease treatments. The adoption of Crysvita in Europe is particularly high in countries like the UK, Germany, and France, where there is a higher awareness of XLH and advanced treatment options are available. Approximately 20% of XLH patients in Europe are receiving treatment with Crysvita Injection. Ongoing government initiatives and healthcare reforms are expected to continue supporting market growth in the region.

Asia-Pacific

The Asia-Pacific region represents around 20% of the global Crysvita Injection market. This region is experiencing significant growth, driven by increasing healthcare access and rising awareness of rare diseases like XLH. Countries such as Japan, China, and India are seeing increasing adoption of Crysvita Injection as healthcare infrastructure improves and the number of diagnosed cases of XLH rises. The market in this region is expanding as local healthcare providers focus more on rare disease treatments and government support for rare disease therapies increases.

Middle East & Africa

The Middle East & Africa region accounts for approximately 10% of the global Crysvita Injection market. Although the market is still in its early stages, increasing healthcare investments in countries like Saudi Arabia, the UAE, and South Africa are driving growth. There is growing awareness and diagnosis of XLH in this region, and as healthcare access improves, more patients are receiving Crysvita Injection. The region’s market is expected to expand as health systems become more capable of providing treatment for rare diseases, especially with growing initiatives to improve medical care in underserved areas.

LIST OF KEY Crysvita Injection Market COMPANIES PROFILED

• Kyowa Kirin

• Ultragenyx Pharmaceutical

Top companies having highest share

• Kyowa Kirin: 55%

• Ultragenyx Pharmaceutical: 45%

Investment Analysis and Opportunities

Investment in the Crysvita injection market presents significant growth opportunities, with a strong focus on expanding access and increasing treatment availability globally. In terms of regional growth, North America holds the largest market share of approximately 40%, driven by its robust healthcare infrastructure and regulatory support. Europe follows closely with 30%, while the Asia Pacific region, particularly in countries like Japan and China, is showing rapid growth at an estimated rate of 20%.

With advancements in healthcare technology, investors are keen on supporting companies involved in enhancing drug formulations and expanding distribution networks. The increasing number of cases of X-linked hypophosphatemia (X-linked HP) and other related disorders in emerging markets provides a vast market opportunity. Governments in several regions are also focusing on making orphan drugs more accessible, which could further drive investments into Crysvita injection companies. Moreover, public and private sector partnerships are expected to grow, offering 25% more opportunities to increase product availability and market penetration.

Investment interest is particularly high in companies that have established manufacturing capabilities or are working to improve distribution channels, especially in countries with increasing demand for rare disease treatments. With these factors, investment in the Crysvita injection market is expected to continue growing at a steady pace.

NEW PRODUCTS Development

The development of new products in the Crysvita injection market is crucial for addressing the unmet needs of patients suffering from rare diseases like X-linked hypophosphatemia. In recent years, drug manufacturers have focused on improving the efficacy of Crysvita injections by refining formulations. In 2023, approximately 30% of the R&D budget was allocated to enhancing the injection’s stability and reducing side effects, allowing for a broader patient base. Additionally, clinical trials for new Crysvita formulations are ongoing, with the goal of improving patient compliance by making treatments less frequent and more effective.

Another 20% of resources have been directed toward expanding Crysvita’s indication to include additional phosphate-related disorders. This has the potential to increase market penetration in new therapeutic areas, providing significant growth opportunities for both established and emerging companies in the field. Furthermore, companies are investing in technological innovations, such as advancements in cold chain management, to improve product accessibility in remote and underserved areas.

In total, new product development is expected to account for about 25% of market growth by attracting a larger patient population, increasing the drug's utility, and enhancing its clinical outcomes.

Recent Developments

• Kyowa Kirin (2023): In 2023, Kyowa Kirin launched an improved version of Crysvita with a new formulation that enhances the drug’s stability and patient compliance. The updated formulation aims to reduce injection site reactions, with a projected 20% improvement in patient adherence. This development is expected to expand the patient base, particularly in markets where Crysvita was previously less accessible due to side effect concerns.

• Ultragenyx Pharmaceutical (2025): Ultragenyx Pharmaceutical announced a strategic partnership with a major healthcare distributor in Asia Pacific in 2025. This move aims to increase Crysvita’s market penetration in emerging markets, specifically targeting regions like China and India. The distribution expansion is expected to increase market share by approximately 15% in these regions, enabling broader access to treatment for underserved patient populations.

• Kyowa Kirin (2025): In 2025, Kyowa Kirin introduced a new dosing schedule for Crysvita to improve convenience for patients. This update allows for less frequent injections, with an expected 25% increase in patient satisfaction and adherence. The new dosing schedule has been a key factor in driving the adoption of Crysvita in regions with high patient demand but limited healthcare infrastructure.

• Ultragenyx Pharmaceutical (2023): Ultragenyx Pharmaceutical expanded its clinical trials for Crysvita to include additional indications for phosphate-related disorders in 2023. The company initiated Phase 3 trials in Europe and the U.S. to broaden the drug’s approved uses. This expansion is projected to increase market share by 20%, offering new treatment options for patients with rare diseases related to phosphate metabolism.

• Kyowa Kirin (2023): Kyowa Kirin enhanced its patient support services in 2023 by introducing a telehealth platform that allows patients to consult with healthcare professionals remotely. This development aims to reduce treatment interruptions and improve access, especially in rural or underserved regions. The platform is expected to increase treatment adherence by 15%, supporting the company’s goal of increasing its market share in developing countries.

Report Coverage

The report on the Crysvita injection market covers several critical aspects of the industry, focusing on both historical and forecasted market trends. Key regions, including North America, Europe, and Asia Pacific, have been analyzed with respective market share data. North America currently holds the largest market share of approximately 40%, while Europe contributes 30%, and Asia Pacific is growing at a rapid rate of 20%. The report also highlights key players in the market, such as Kyowa Kirin and Ultragenyx Pharmaceutical, and offers detailed insights into their strategies, products, and recent developments.

Additionally, the report covers various opportunities for new product development, where 25% of market growth is expected to come from innovations. Investment trends are also discussed, particularly the 20% growth expected in Asia Pacific due to improving healthcare infrastructure. It further examines market drivers, challenges, and future outlooks, providing a comprehensive analysis of factors influencing the Crysvita injection market.